Citi raised the firm’s price target on PTC Therapeutics to $67 from $61 and keeps a Buy rating on the shares. The company’s Q1 product revenue beat, driven by strong Translarna sales, the analyst tells investors in a research note. The firm sees a "catalyst rich" Q2 for PTC Therapeutics.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on PTCT:
- William Blair healthcare analysts to hold an analyst/industry conference call
- PTC Therapeutics reports Q1 EPS ($1.88), consensus ($1.39)
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- PTC Therapeutics participates in a conference call with JPMorgan
- Is PTCT a Buy, Before Earnings?
